-Bloomberg It wasn't the Gettsyburg Address -- unless it's poker faces we're comparing. Future historians aren't going to be parsing Prime Minister Manmohan Singh's speech for hidden meanings, and rhetoricians won't be delighting in the majesty of its style and the compression of its effects. It inflamed no passions, as did Mitt Romney's words about the "47 percent," and asserted no big idea or thesis, unless there was one contained in the...

-The Times of India The government is facing a pincer attack over its reform decisions with opposition parties ranging from BJP to the Left planning nation-wide protests, possibly on the same day, against UPA-2's bid to allow FDI in sectors like multi brand retail and civil aviation. Regional parties like Samajwadi Party and Janata Dal (U) also joined the chorus of protests, demanding a rollback of the hike in diesel prices along...

-The Economic Times India's drug price regulator has initiated a process to end the 16-year freedom enjoyed by foreign drug makers to fix the retail price of their imported medicines in the country. The National Pharmaceutical Pricing Authority (NPPA) has written to the department of pharmaceuticals to amend the Drugs (Prices Control) Order of 1995, its chairman CP Singh told ET. The amendment will allow NPPA to seek details of the methodology adopted...

-The Business Standard State must get out of insulin price-setting The National Pharmaceutical Pricing Authority, or NPPA, has turned down the request of drug companies to raise insulin prices. Domestic insulin-makers Biocon and Cadila had argued that the cost of production and packaging had become higher, and multinational corporation Eli Lilly wanted the depreciation in the rupee vis-à-vis the dollar to be factored into the price. The NPPA says it has...

-The Economic Times It's not just the drug regulator, where a parliamentary panel has alleged corruption, failing in its job. Drug regulation across entities that dot this broad landscape is in poor health and ineffective. In May, when a Parliamentary panel, during a routine examination of healthcare regulatory bodies, alleged corruption in the approval of new drugs, it was merely pointing out one symptom. Such symptoms pervade the entire drug regulation landscape,...